Compare Gartner Inc (IT) vs Eli Lilly And Co (LLY) Price & Performance

Gartner (IT) trades at $141.06, up 0.62% today, with a neutral technical signal and mixed analyst sentiment. The stock shows strong profitability with a net income margin of 11.44% and has beaten earnings estimates for three consecutive quarters. Recent news highlights its leadership in Gartner Magic Quadrant reports, but an ongoing legal investigation adds uncertainty. Cash flow turned negative in 2025 due to high financing outflows, though revenue remains stable around $6.5 billion.

The outlook is cautiously optimistic with a consensus price target of $157.60 suggesting 12% upside. Key opportunities include steady revenue growth and high ROE of 94.88%, but risks involve the legal probe, elevated P/B ratio of 148.08, and volatile cash flows. Investors should weigh strong fundamentals against near-term headwinds.

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.